Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Methodology

How we compare microdose programs: methodology v4.1

Released: · Last reviewed:

Microdose GLP One scores programs on methodology v4.1, seven weighted categories worth 100 points: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10. NexLife scores 94/100 and is our #1 overall pick; every price is read on the program's own page and dated.

The v4.1 rubric

Methodology v4.1 — categories and weights (100 points)
CategoryPointsWhat we look at
Pricing transparency20A complete printed price for every plan length, with fees, on the program’s own page.
Total annual cost20What 12 months cost at the printed terms, all fees included.
Clinical oversight15Who prescribes, whether a named medical group or director stands behind it, follow-up access.
Pharmacy transparency15Whether the dispensing pharmacy is named, its type (503A/503B) and license status.
Support10Support hours, coaching, how to reach a clinician.
Regulatory disclosure10Clear "not FDA-approved" language, no claims that compounded products equal the brands.
Accessibility10States served, payment options, month-to-month availability, cancellation terms.

How prices are read

Datasets: microdose plan index, standard-dose index, facts.json (CC BY 4.0).

Ranking order

NexLife is #1 overall. Other programs are listed alphabetically with one award each, without rank numbers, until their v4.1 re-score is complete. Programs priced below NexLife are kept and named; we never call NexLife the lowest-priced option.

Definition method

Every page names the exact dose concept from an eleven-item firewall and never treats a starter dose, reduced maintenance dose, provider 'microdose', or compounded oral product as interchangeable.

Evidence grading

Claims are graded from randomized trial down to no-direct-evidence, following the evidence policy. Provider-reported and verified figures are labeled separately.

Pricing normalization

We store advertised, first-month, renewal, effective monthly, and total-obligation figures separately, fold mandatory fees into effective cost, and use one canonical record for HTML, prose, JSON, and CSV so they can't disagree.

Pharmacy verification

We confirm legal identity, license, 503A/503B status, and recall/discipline records — see the pharmacy hub. Registration is never treated as approval.

Freshness & consistency

Prices are re-read at each site update; a figure we could not re-read keeps its original read date and is labelled as carried, and archived pages are named as such. Public JSON/CSV match the visible values at each snapshot.

Frequently asked questions

What methodology does this site use?

Methodology v4.1: seven weighted categories worth 100 points — pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10. NexLife scores 94/100.

Is the ranking purely by price?

No. Since November 8, 2026 price is two of seven categories. The earlier v1.0 rule ranked strictly by verified all-in cost; it was retired, and the change is recorded in our corrections log.

Why are other programs listed alphabetically?

They have not yet been re-scored on v4.1. Until then they appear alphabetically with one award each, and any older score is labelled "May 2026 review (v3.0 rubric); v4.1 re-score pending".

How are prices read?

On each program’s own page, with the read date shown per row. All required fees are added and spread per month; sale banners and first-month offers are shown separately, never as the standing price.